The standard-titration is careful and slow, to avoid incompatibilities, including cognitive side effects and rashes. 3 Commonly the dosage ranges from 5 to 7.5 mg/(kg day) with an increase of 5-7.5 mg/(kg day) every 3-7 days up to a final dosage of 30 mg/(kg day) in children and 20-25 mg/(kg day) in adolescents and adults. A sufficient serum level is reached after 2-6 weeks.
Intravenous rapid loading is possible and well tolerated, 4 whereas the VPA pharmacokinetics are dependent on age, induction status, and formulation. 5 An oral scheme has already been established for phenytoin. 6 A rapid oral loading of VPA was suggested for the therapy of acute mania for adult psychiatric patients. 7, 8 Good et al. 9 showed the possibility of quick oral loading of VPA in child psychiatry inpatients with a dosage of 15 mg/(kg BW) after a period of 5 days. Side effects were observed in overweight children. Summary Valproic acid (VPA) is considered to be a drug of first choice for the therapy of generalized and focal epilepsies. Due to its broad field of application and its good compatibility, VPA is one of the most frequently prescribed antiepileptic drugs (AED) worldwide.
Previous studies have examined the safety and tolerability of rapid intravenousloaded VPA in the treatment of epilepsy and status epilepticus, but rapid oral loading has not been evaluated in paediatrics systematically in the past.
The standard titration scheme takes 10-14 days, some physicians prefer a slower titration of up to 4 weeks. At many institutes, especially children are treated as inpatients until the desired dosage is reached. This causes high costs to the health system and is very inconvenient for the families affected.
We have developed a new loading scheme to achieve a therapeutic serum level on the third day of treatment, in order to minimize the time between the beginning of the therapy and reaching the therapeutic serum level. This is the first attempt at doing this with VPA for children with epilepsy. # 2006 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Methods
As opposed to the saturation scheme of Martinez et al. 8 used in acute manic adults, we have initiated a scheme for rapid oral saturation, starting with 30 mg/kg as single dose, followed by 45 mg/kg on the second day divided in two doses and 30 mg/ (kg day) on day 3 for children with epilepsy. The serum level of VPA, coagulation parameters, transaminases, lipase and full blood count were controlled on the third day of therapy.
Results
We have applied this scheme in 35 children (as shown in Table 1 ) and adolescents in our hospital. Twenty-one were male, 14 female, the age ranged from 9 months up to 16 years (average 5.5 years). The spectrum of diseases ranged from relapsing febrile convulsions, grand-mal epilepsy to epilepsy with grand-mal on awakening (Janz-Syndrome).
All of the patients reached a sufficient fasting serum level of VPA on the third day (average 98.2 mg/l; median 101 mg/l; 48-146 mg/l). Two of the patients, 14 and 16 years old, both with juvenile myoclonic epilepsy had maximum serum levels of 140 and 146 mg/l, respectively, and developed an increase of the serum ammonia level (98 and 200 mmol/l) with nausea and fatigue. Shortly after we reduced the daily dosage, the symptoms disappeared and the serum ammonia level normalized. All other children did not complain of any side effects, such as drowsiness and other CNS side effects or gastrointestinal adverse reactions during the first 30 days of treatment. No alterations of any Oral rapid loading of valproic acid 631 febrile convulsions  86  102  25  f  9  IGE  113  43  26  f  1  Relapsing febrile convulsions  122  84  27  m  8  IGE  127  127  28  m  1  Encephalopathy  TPM  88  85  29  m  1  Infantile grand-mal epilepsy  109  109  30  m  3  Infantile grand-mal epilepsy  -87  87  31  f  16  Epilepsy with grand-mal on awakening  -140  79  32  m  2  Infantile grand-mal epilepsy  -126  102  33  m  9  IGE  89  92  34  m  6  IGE  123  77  35  f  0.7  Relapsing febrile convulsions  -83  92 laboratory findings were discerned, seizure control was achieved and remained excellent thereafter. We controlled the fasting serum level of VPA 30 days later and the serum level was still at a therapeutic level (average 97.8 mg/l; median 91 mg/l).
Conclusion
Our findings suggest that a new rapid titration scheme of oral VPA-treatment is feasible. We reached a sufficient serum level on the third day of therapy and the patients did not show any severe side effects or incompatibilities.
Two of our patients, both adolescents, showed a mild increase of the serum ammonia level related to a high serum level of VPA. In these two adolescents we applied the same dosage of 30 mg/(kg BW) as in the children. Commonly a final dosage of 20 mg/ (kg BW) is aimed at in adolescents and adults as compared to 30 mg/(kg BW) in infants. The side effects we encountered in the adolescents corroborate the clinical experience that 20 mg/(kg BW) should be aimed at this age group.
The results suggest that VPA can be safely administered by rapid oral loading in children with epilepsy and that using a standard loading protocol can result in therapeutic serum levels in patients in 3 days or less.
In contrast to the conventional scheme, our newly initiated rapid oral loading of VPA shortens the time as inpatient and in consequence the costs and the inconvenience caused to the families. Furthermore, seizure control can be obtained much faster than with conventional loading schemes.
In contrast to intravenous rapid loading our new scheme is less invasive and less painful, but also very effective.
Our next step is to prospectively compare our new scheme versus the standard titration.
